54 Result(s)

Article

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis

Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate to severe plaque psoriasis in the POETYK PSO-1 and PSO-2 clinical trials. In the study reported here, we aimed to determin...

April W. Armstrong, Sang Hee Park, Vardhaman Patel… in Dermatology and Therapy (2024)

Article

Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis

Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patient...

April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt… in Dermatology and Therapy (2024)

Article

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRI...

April W. Armstrong, Tarannum Jaleel, Joseph F. Merola… in Dermatology and Therapy (2024)

Article

Brodalumab: 5-Year US Pharmacovigilance Report

Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have ...

Mark G. Lebwohl, John Y. Koo, April W. Armstrong… in Dermatology and Therapy (2024)

Article

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey

While multiple treatments are available for moderate to severe psoriasis, patient preferences are rarely systematically studied. This study aims to identify factors associated with choice of a new once-daily o...

April W. Armstrong, Sayeli Jayade, Sanika Rege, Namita Joshi… in Dermatology and Therapy (2024)

Article

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

April W. Armstrong, Sang Hee Park, Vardhaman Patel… in Dermatology and Therapy (2023)

Article

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared the long-term efficacy of deucr...

April W. Armstrong, Sang Hee Park, Vardhaman Patel… in Dermatology and Therapy (2023)

Article

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

Deucravacitinib, a newly approved oral medication for the treatment of patients with moderate to severe plaque psoriasis, demonstrated efficacy versus apremilast and placebo in two phase 3 randomized controlle...

April W. Armstrong, Richard B. Warren, Yichen Zhong, Joe Zhuo… in Dermatology and Therapy (2023)

Article

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials

Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD). To further explore the long-term efficacy of tra...

Eric L. Simpson, Andrew E. Pink… in American Journal of Clinical Dermatology (2023)

Article

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis

The treatment landscape for moderate-to-severe atopic dermatitis (AD) continues to expand. This network meta-analysis (NMA) updates a previously conducted NMA to include data from the most recent phase 3 trial...

Jonathan I. Silverberg, H. Chih-ho Hong, Brian M. Calimlim… in Dermatology and Therapy (2023)

Article

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success

Chronic spontaneous urticaria (CSU) is a complex skin disease characterized by the spontaneous appearance of wheals, angioedema, or both, for more than 6 weeks. Many patients experience a relapsing–remitting d...

April W. Armstrong, Weily Soong, Jonathan A. Bernstein in Dermatology and Therapy (2023)

Article

The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness

Immune-modulating treatments are used in dermatology for a variety of conditions. The authors aim to review the data regarding the safety of these treatments during the COVID-19 pandemic, namely the risk of in...

Nicole Maynard, April W. Armstrong in Current Dermatology Reports (2023)

Article

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

Guselkumab, an anti-interleukin-23 biologic therapy, has been shown to significantly reduce disease activity and improve patient-reported outcome measures (PROMs) among patients with moderate-to-severe plaque ...

April W. Armstrong, Timothy Fitzgerald, Robert R. McLean… in Dermatology and Therapy (2023)

Article

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

In clinical trials, treatment with the interleukin-23 inhibitor guselkumab was associated with significantly improved disease severity and patient-reported outcome measures (PROMs) among patients with moderate...

April W. Armstrong, Timothy Fitzgerald, Robert R. McLean… in Dermatology and Therapy (2023)

Article

A Response to: Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, Yan Wang… in Dermatology and Therapy (2022)

Article

Undermining during cutaneous wound closure for wounds less than 3 cm in diameter: a randomized split wound comparative effectiveness trial

Undermining is thought to improve wound outcomes; however, randomized controlled data regarding its efficacy are lacking in humans. The objective of this randomized clinical trial was to determine whether unde...

Jayne Joo, Aunna Pourang… in Archives of Dermatological Research (2022)

Article

Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis

Achievement of remission in psoriatic arthritis is a key goal for patients and clinicians, yet definitions of remission may vary. Previous efforts have utilized multidomain measures such as minimal disease act...

George Gondo, Megan Mosca, Julie Hong, Emanual Maverakis… in Dermatology and Therapy (2022)

Article

Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis

The comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis (AD) has not been systematically assessed using recent phase 3 data. This network meta-analysis assesses the com...

Jonathan I. Silverberg, H. Chih-ho Hong, Jacob P. Thyssen… in Dermatology and Therapy (2022)